Next, we performed immunohistochemical staining to measure the expression status of PRMT5 in pancreatic cancer patients, and our results demonstrated that PRMT5 expression was significantly higher in PDAC tumor samples than in adjacent normal tissues (Fig. 1b and c). This evidence concerns the gene PRMT5 and pancreatic neoplasm.